Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

406 articles

Keyword: nanotechnologyClear keyword
Frontiers in pharmacology2026ReviewDrug Delivery

1. Multi-target neuroprotective mechanisms of epigallocatechin-3-gallate (EGCG) in stroke: from molecular pathways to nanomedicine delivery and clinical translation

Yuan Y, Xie C, Huang Y, Xi J, Wang P, Chen Z, Et Al.

Stroke ranks among the leading global causes of mortality and permanent disability. Its secondary brain injury arises from multiple interrelated pathological cascades, including oxidative stress, neuroinflammation, disrupted autophagy-apoptosis balance, excitotoxicity, iron dyshomeostasis, and blood-brain barrier (BBB) dysfunction. Although intravenous thrombolysis and mechanical thrombectomy have greatly improved the efficacy of acute reperfusion therapy, effective neuroprotective regimens for secondary brain injury remain scarce.

EGCGclinical translationnanotechnologyneuroprotectionstroke
Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes, licensing and GMP supply.InvestorsDownload our capabilities deckPlatform, pipeline milestones, manufacturing and partnership models in one PDF.
Articles | Brilliant Blue Biosciences